276 related articles for article (PubMed ID: 8059453)
1. [Screening of newborn infants for cystic fibrosis. A combined analysis of immunoreactive trypsin and delta F508 mutation--a screening without false positive results].
Nørgaard-Pedersen B; Høgdall EV; Arends J; Vuust J
Ugeskr Laeger; 1994 Jun; 156(25):3757-60. PubMed ID: 8059453
[TBL] [Abstract][Full Text] [Related]
2. [Mucoviscidosis screening of newborn infants in the Dresden district. Results from 1 June 1996 to 31 March 2000].
Wunderlich P; Stopsack M; Paul KD; Rösen-Wolff A
Dtsch Med Wochenschr; 2000 Nov; 125(45):1356-60. PubMed ID: 11109423
[TBL] [Abstract][Full Text] [Related]
3. Screening for cystic fibrosis in dried blood spots of newborns.
Audrézet MP; Costes B; Ghanem N; Fanen P; Verlingue C; Morin JF; Mercier B; Goossens M; Férec C
Mol Cell Probes; 1993 Dec; 7(6):497-502. PubMed ID: 8145780
[TBL] [Abstract][Full Text] [Related]
4. [A new strategy of neonatal screening for cystic fibrosis. The association of immunoreactive trypsin and molecular biology in dried blood].
Laroche D; Peres O; Briard ML; Lemonnier F; Pasquet-Ferre C; Blandin C; Travert G; Fernandez Y
Arch Fr Pediatr; 1990 Apr; 47(4):251-3. PubMed ID: 2363611
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis screening in neonates--measurement of immunoreactive trypsin and direct genotype analysis for delta F508 mutation.
Larsen J; Campbell S; Faragher EB; Götz M; Eichler I; Waldherr S; Dobianer K; Spona J
Eur J Pediatr; 1994 Aug; 153(8):569-73. PubMed ID: 7957403
[TBL] [Abstract][Full Text] [Related]
6. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
7. Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis.
Farrell PM; Koscik RE
Pediatrics; 1996 Apr; 97(4):524-8. PubMed ID: 8632940
[TBL] [Abstract][Full Text] [Related]
8. [Mucoviscidosis screening with immunoreactive trypsin].
Eber E; Ellemunter H; Engele H; Götz M; Grünberger W; Haas J; Janisch H; Leodolter S; Litscher H; Müller G
Wien Klin Wochenschr; 1992; 104(22):681-5. PubMed ID: 1475973
[TBL] [Abstract][Full Text] [Related]
9. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
10. The pancreatitis-associated protein (PAP). A new candidate for neonatal screening of cystic fibrosis.
Iovanna JL; Férec C; Sarles J; Dagorn JC
C R Acad Sci III; 1994 Jun; 317(6):561-4. PubMed ID: 7527291
[TBL] [Abstract][Full Text] [Related]
11. DNA analysis of cystic fibrosis in Brazil by direct PCR amplification from Guthrie cards.
Raskin S; Phillips JA; Krishnamani MR; Vnencak-Jones C; Parker RA; Rozov T; Cardieri JM; Marostica P; Abreu F; Giugliani R
Am J Med Genet; 1993 Jul; 46(6):665-9. PubMed ID: 8362909
[TBL] [Abstract][Full Text] [Related]
12. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
[TBL] [Abstract][Full Text] [Related]
13. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
14. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies.
Wilcken B; Wiley V; Sherry G; Bayliss U
J Pediatr; 1995 Dec; 127(6):965-70. PubMed ID: 8523199
[TBL] [Abstract][Full Text] [Related]
15. Newborn screening for cystic fibrosis in Wisconsin: first application of population-based molecular genetics testing.
Farrell PM; Aronson RA; Hoffman G; Laessig RH
Wis Med J; 1994 Aug; 93(8):415-21. PubMed ID: 7975706
[TBL] [Abstract][Full Text] [Related]
16. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels.
Massie RJ; Wilcken B; Van Asperen P; Dorney S; Gruca M; Wiley V; Gaskin K
J Pediatr; 2000 Aug; 137(2):214-20. PubMed ID: 10931414
[TBL] [Abstract][Full Text] [Related]
18. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
[TBL] [Abstract][Full Text] [Related]
19. [Neonatal screening for cystic fibrosis].
Tellería Orriols JJ; Alonso Ramos MJ; Garrote Adrados JA; Fernández Carvajal I; Blanco Quirós A
An Esp Pediatr; 2002 Jul; 57(1):60-5. PubMed ID: 12139895
[TBL] [Abstract][Full Text] [Related]
20. Neonatal screening for cystic fibrosis in the Trent region (UK): two-stage immunoreactive trypsin screening compared with a three-stage protocol with DNA analysis as an intermediate step.
Pollitt RJ; Dalton A; Evans S; Hughes HN; Curtis D
J Med Screen; 1997; 4(1):23-8. PubMed ID: 9200059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
